MedTrace Logo

Educational Training Influence in Patients With PAH(Pulmonary Artery Hypertension) on Inhaled Ventavis Treatment Adherence Evaluated Trough INSIGHT System

NCT01468545 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38

Last updated 2014-08-29

No results posted yet for this study

Summary

Ventavis it's a treatment for pulmonary hypertension, administered by an inhaler called I-Neb.

In these patients, the non compliance of the treatment becomes its ineffective and increases the complications and mortality of the disease.

It is therefore important to know which the adherence of patients to their treatment is and try to promote it.

One possibility to reach a good level of adherence is the patient education regarding the drug administration and also to comply as better is possible the recommendations of the physician.

For this reason, the objective of our study is to demonstrate improvement in the level of treatment compliance when they follow a strategy of continuing education, assessed by the device and software called Insight.

The only special procedure to participate in the study then is that patients involved could receive more training than usual.

Investigators expect involving in this study around 50 patients in treatment with Ventavis and diagnosed of Pulmonary Arterial Hypertension in 10-12 hospitals throughout Spain.

The patients who participated in the study will be followed for 12 months from inclusion in the study and will perform around 5 visits in total.

Conditions

Interventions

OTHER

Iloprost (Ventavis inhaled, BAYQ6256)

An extra educational reinforcement at baseline and at 6 months will be given to a group of patients

OTHER

Iloprost (Ventavis inhaled, BAYQ6256)

No extra educational reinforcement.

Sponsors & Collaborators

  • Dra. Pilar Escribano Subías - Coordinator - HU 12 de Octubre - Madrid (Spain)

    collaborator UNKNOWN

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-01-31
Completion
2014-06-30

Countries

  • Spain

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01468545 on ClinicalTrials.gov